INTRODUCTION

Visceral leishmaniasis (VL), also known as kala-azar, is a protozoal parasitic disease caused by *Leishmania donovani* complex, and transmitted to man by the bite of infected female sandfly *Phlebotomus* spp. in Africa. VL is an infection of the reticulo-endothelial system characterized clinically by a chronic febrile course, and associated with loss of weight and hepato-splenomegaly. The diagnosis is usually established by identification of the parasite in aspirate material from bone marrow, spleen, or lymph nodes. The World Health Organization estimates the annual global rate for VL prevalence and incidence at 2.5 and 0.5 million cases, respectively. VL causes 60-70 thousand deaths every year.

Many factors have contributed to the worldwide increased interest in basic and clinical research on VL. First, VL is a vector-borne disease which is adapting to environment changes, and spreading into urban and suburban areas, such as in Brazil.
Second, VL is recognized as a major opportunistic infection associated with HIV/AIDS patients, such as in Ethiopia.\(^4\) Third, the expense and side effects of drug therapy, the lack of an effective vaccine, the diversity of the sand fly biology, and the changing virulence behaviour of the causative protozoan: continue to represent a challenge in the understanding and management of VL. Finally, global warming is being suggested as a possible reason for the eventual spread of diseases now seen primarily in the tropics, such as VL, to more temperate climates.\(^5\) An interesting report from Britain is presuming that VL may become endemic in southern England, based on a prediction that by the year 2025 that area will have a climate like that currently seen in the south of France where VL disease and vector are present.\(^6\)

VL is an important health problem in east African countries including Kenya, South Sudan, Uganda, Ethiopia, Somalia, and Sudan.\(^7\)-\(^10\) In Kenya, VL is encountered mainly in the region of Baringo, however, changing improved lifestyle has led to a decreased incidence rate of VL among males in this country. In West Pokot region of Uganda, the majority of VL patients belong to the pediatric age group. In Ethiopia, VL is encountered mostly as an opportunistic infection in HIV/AIDS adult patients, and the mortality rate is relatively high. In South Sudan, most of VL cases were reported from Upper Nile Province region during a large epidemic outbreak that started in the year 1984 and claimed around 100 thousands of human lives. In Somalia, VL has been reported from the region of Shebelle River in the south of the country. Transmission of VL to man in this country is believed to be mainly anthroponotic (from a human reservoir).

In Sudan, the first VL patient was described in the year 1904. Transmission dynamics are believed to include both zoonosis (from an animal reservoir) as well as anthroponosis. The sandfly vector is Phlebotomus orientalis. The leishmania isolated from human and sandfly possess three zymodemes: MON-18, MON-30, and MON-82 which all belong to *Leishmania donovani* complex.\(^1\) The typical clinical features include: fever, weight loss, hepatosplenomegaly, and pancytopenia. Post kala-azar dermal leishmaniasis (PKDL), a skin complication of VL encountered after or during treatment, has been reported in up to 58% of patients.\(^11\) Genetic susceptibility is an epidemiologic feature in Sudanese VL.\(^12\) This genetic feature was suggested following observations of marked variations in incidence of clinical disease among populations of different ethnicities sharing the same immediate environment and transmission exposures.

All patients of the present study are, originally, from the White Nile Province region (WNP) in southern part of Sudan. The WNP region is 120km south of the capital Khartoum where the patients were referred to, and managed in Tropical Diseases Hospital (TDH). Studies on VL from the WNP region are scarce, and in this report we present our findings on the clinical and demographic features of VL patients from this region.

**METHODOLOGY**

This is a descriptive cross sectional hospital-based study. The study population are 71 VL patients who are originally from rural areas in WNP region which is located in southern part of Sudan. The patients were managed in TDH in the capital Khartoum. TDH is a Ministry of Health referral hospital, and affiliated to Faculty of Medicine, Omdurman Islamic University, Sudan. This hospital was founded in 1974 for research, service, and training on tropical diseases, mainly visceral leishmaniasis, malaria, and schistosomiasis. The Quality Control Unit of TDH is operated by trained medical officers who verify the documentation and transfer of patient data from the hospital medical records into an electronic software system.

Confirmation of diagnosis for VL in the study patients was carried out by (1) Demonstration of amastigote stage of parasite in aspirate material from lymph node, bone marrow, or spleen using direct light microscopy or (2) Positive serology using Direct Agglutination Test (DAT) at a significant titer of 1:6400 or more, combined with a negative Leishmanin Skin Test (LST). The clinical features and demography of confirmed VL patients during the period 2006-2010, were retrieved from the hospital records electronic system. Next, the patients' information was entered onto a standardized data sheet developed by us. The data included VL symptoms, signs, laboratory findings, drug therapy, patient gender, and age.

Computer assisted analysis, using statistical program for social sciences (SPSS) version 16, was employed. The study was approved by the Research and Ethics Committee of Faculty of Medicine, Omdurman Islamic University, Sudan.

**RESULTS**

Table-I shows the clinical symptoms of the 71 VL study patients. Fever was encountered in 68 (95.8%) of cases. The duration of fever was calculated
in weeks, and ranged between 1-72 weeks with a mean of 10.8 ± 11.3 standard deviation (SD). Other symptoms encountered were abdominal pain (67.6%), loss of appetite (56.3%), weight loss (85.9%), epistaxis (29.6%), diarrhea (25.4%), cough (39.4%) and joint pains (29.6%).

Table-II shows the clinical signs of the 71 VL study patients. Pallor (83.1%), skin pigmentation (8.5%), lymphadenopathy (50.7%), splenomegaly (93%), hepatomegaly (73.2%), ascites (9%), and lower limbs oedema (14.1%). In the patients who had splenomegaly; the median spleen size on admission to hospital was 8 cm (range, 2cm – 26cm).

Table-III shows the gender and age distribution of the 71 VL study patients. Males are at higher risk for VL as compared to females with a ratio of 3:1 (53 vs 18). VL was largely a disease of children with 42 (59.1%) occurring among those aged < 15 years. Around quarter of the patients (23.9%) were under 5 years of age.

Table-IV shows the haematology findings of the 71 VL study patients. The most notable feature was anaemia which was found in 77% of patients. They had Hb < 11g/dL. The mean value of haemoglobin among all the study patients was 7.6 g/dL on admission to hospital.

The results of drug outcome showed that all patients received sodium stibogluconate (SSG) with a cure response in 67 (94.4%) cases. Four patients died giving a case fatality rate of 5.6%.

**DISCUSSION**

Before the year 1988, VL did not exist in WNP region, southern Sudan. The Upper Nile Province region which is bordering WNP region southward had experienced a large epidemic outbreak of VL that started during 1984 and went on until 1994.1 Retrospect analysis of population migration has supported the assumption that VL of WNP region was spread from their neighbouring region. Further support was provided by the concept that VL is an emerging disease where the sandfly vector and the protozoal parasite are able to adapt and spread into intra-domiciliary and peri-urban environments.13 In Brazil, it was documented that during the late 1980s VL has expanded into previously unaffected rural areas and into the outskirts of large cities.14 This situation has resulted into undue delay in diagnosis.
of VL, as well as rise in mortality rates in urban VL cases, because the disease was under-estimated by medical practitioners. In Nepal, VL case reports were found to be rising in areas of the country previously not recognized as endemic.15

The WNP region is located in southern part of Sudan, around 120 km south of the capital Khartoum, and bordering northward of Upper Nile Province region, a known VL endemic area in Sudan. The climate in WNP region is essentially subtropical, and agriculture is an important part of the population activities, with abundant Acacia seyal and Balanites aegyptica vegetations.16 Together with other socio-demographic factors, these climate characteristics favours VL transmission among local populations. The first documented cases of VL from WNP region (16 in total) were described in 1988 among local inhabitants of small villages.17 Most of the subsequent cases showed a paediatric age profile, suggesting that adults are immune, and indicating an endemic pattern of VL. Thus, in retrospect analysis, we understand that VL cases in WNP region were sporadic case reports from a non-endemic area, during the late 1980s through into the 1990s, following the large epidemic outbreak in the neighbouring region. Next, the appearance of clusters of VL among children during the second half of the decade starting the year 2000 (covering the present study period) has provided evidence that the disease has changed to the pattern of an endemic area.

The clinical features of VL patients, in this study, are more or less similar to the disease pattern in South America and Asia.18,19 Fever, hepatosplenomegaly, loss of weight, and pancytopenia are the classic features of VL which were manifest in the majority of our patients, at the time of hospital admission, Table I, II, and IV. VL in WNP region is, relatively, of recent encounter to medical practitioners in this region, and they used to underestimate VL and diagnose it as malaria, which is a febrile illness associated with splenomegaly, and endemic in the region. This situation explains the undue delay in VL diagnosis and the late presentation of patients (data not shown) to TDH referral hospital in Khartoum. Comparable to our finding, a study from Pernambuco region in northeastern Brazil has suggested childhood febrile illnesses are being considered as initial diagnoses in urban VL patients.20 Consequently, significant delay of VL diagnosis was encountered and had resulted in increase of mortality rates in that region.

Lymphadenopathy is a common VL clinical feature, described not only in this study, but also in previous literature from east Africa.21 Although this feature is classically labelled as rare in Indian VL, a recent report from Himalayan region (previously non-endemic area), described lymphadenopathy in a series of 18 patients.22 These inter-continental variations are, partly, explainable in terms of genetic factors. Evidence is accumulating that genetic diversity is playing a role in susceptibility to incidence of VL disease and to the severity of its clinical features. For example, in Sudan, tribes of different ethnicities who shared the same immediate environment and same VL transmission exposures were found to show marked variations as regard incidence of clinical disease. A prospective study on these different tribes, using multi-case families, has demonstrated an association link between the gene SLC11A1 (formerly NRAMP1) that codes for innate resistance, and incidence of clinical VL.12 An interesting recent case-control study from India, has demonstrated a single point gene association between clinical VL, and FAM120B gene on chromosome 6q27.23 These findings confirm the potential for genetic polymorphism to act as risk factor for acquisition of VL. Similarly, PKDL, has been described to show an incidence rate as low as 5-10% in Indian VL patients, while an incidence rate as high as 58% was reported in Sudanese VL patients.24 Polymorphism at IFNGR1 gene was found to be associated specifically with PKDL disease susceptibility among Sudanese populations.12

Male patients, in this study, were at higher risk for VL as compared to females with a ratio of 3:1 (53 vs 18). This male gender preponderance, particularly among children, has also been reported from South America.25 However; the underlying aetiology of this VL feature is not fully understood. A study from Brazil has suggested a hormonal factor to be linked with this phenomenon.26 We suggest a potential theoretical risk factor exposing Sudanese male children to sandfly bites: the local social tradition of male children in rural areas who go outdoors for play activities, while females prefer indoor playing.

While the present study contributes important information from Africa to the concept that VL is a disease able to spread and adapt to changing environments, there are some important limitations. First, being a hospital-based study, the actual magnitude of VL cases could have been under-reported. Second, molecular characterization
of leishmania isolates, from humans, animal reservoir, and sandfly vector in WNP region and its neighbouring endemic region is important to add to the clinical and epidemiologic evidence of disease interactions.

CONCLUSION

The present study shows that the clinical features and demography pattern of Sudanese VL are, generally, similar to the picture seen in endemic areas worldwide. Also we described a situation of a VL area with previous sporadic case reports changing into endemic disease pattern. This finding emphasizes the need for research to better understand VL behaviour in non-endemic areas with the objective of developing effective and sustainable control strategies.

REFERENCES

1. Zijlstra EE, Elhassan AM. Leishmaniasis in Sudan: Visceral leishmaniasis. Trans Roy Soc Trop Med Hyg. 2001;95:527-58.
2. World Health Organization. Geneva: WHO; 2010. leishmaniasis; 2010; [cited on 14 August 2012] Available from: http://www.who.int/tdr/diseases-topics/en/
3. Harhay MO, Olliaro PL, Costa DL, Costa CH. Urban parasitology: Visceral leishmaniasis in Brazil. Trends Parasitol. 2011;27(9):403-409.
4. Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray region, Ethiopia. Trop Med Int Health. 2003;8(8):733-739.
5. John DT, Petri WA. Markell and Voge. Medical Parasitology. 9th Edition. USA: Saunders Elsvier: Missouri; 2006:6-21.
6. Killick-Kendrick R. Leishmaniasis: an English disease of the future? Bull Trop Med Int Health. 1996;4:5.
7. Seaman J, Mercer AF, Sondorp E. The epidemic of VL in Upper Nile Province, South Sudan: Course and impact from 1984 to 1994. Int J Epidemiol. 1996;25(4):862-871.
8. Kolaczinski JH, Worku DT, Chappuis F, Rechinger R. Kala-azar control in Uganda. Emerg Infect Dis. 2007;13(3):507-509.
9. Shiddo SA, Mohamed AA, Akuffo HO, Mohamed KA, Herzi AA, et al. Visceral leishmaniasis in Somalia: Prevalence of markers of infection and disease manifestations in a village in an endemic area. Trans Roy Soc Trop Med Hyg. 1995;89:361-365.
10. Robert LL, Shaefler KU, Johnson RN. Phlebotomine sandflies associated with households of human visceral leishmaniasis in Kenya. Ann Trop Med Parasitol. 1994;88(6):649-657.
11. Musa AM, Khalil EA, Raheem MA, Zijlstra EE, Ibrahim ME, Elhassan IM, et al. The natural history of Sudanese post kala-azar dermal leishmaniasis: Clinical, immunological, and prognostic features. Ann Trop Med Parasitol. 2002;96(8):765-772.
12. Blackwell JM, Mohamed HS, Ibrahim ME. Genetics and visceral leishmaniasis in Sudan: seeking a link. Trends Parasitol. 2004;20(6):628-274.
13. Deronimo SM, Oliveira RM, Mackay S, Cost RM, Sweet J, Nascimento ET, et al. An urban outbreak of visceral leishmaniasis in Natal, Brazil. Trans Roy Soc Trop Med Hyg. 1994;88(4):386-388.
14. Silva AO, Silva PB, Silva OV, Melo AA, Leite JA, Pinheiro AJ, et al. Human visceral leishmaniasis in Pernambucano region, Brazil. Trop Med Rev Brazil. 2001;34(Suppl):221.
15. Pun SB, Sato T, Pandey K, Pandey BD. Changing trends in visceral leishmaniasis: 10 years experience at a referral hospital in Nepal. Trans Roy Soc Trop Med Hyg. 2011;105:550-554.
16. Widaa SF, Ahmed KA, Bari AA, Ali MM, Ibrahim MA, Bashir MA, et al. Sandflies (Diptera: Psychididae) in a focus of visceral leishmaniasis in White Nile Province, Sudan. Memorial Institute Oswaldo Cruz. (Brazil). 2012;107(4):470-475.
17. Khalil EA, Musa AM, Elgawi SH, Meshasha A, Gameraldawla I, Elhassan MO, et al. Revival of a focus of visceral leishmaniasis in Sudan. Ann Trop Med Parasitol. 2008;102(1):79-80.
18. Jones BR, Lourenco B. A prospective study of visceral leishmaniasis in an endemic area in Brazil. J Infect Dis. 1996;154:639-649.
19. Bhattacharyya SK, Sur D, Karbwang J. Childhood visceral leishmaniasis. Indian J Med Res. 2006;123:353-356.
20. Queiroz MJ, Alves JC, Correia JB. Visceral leishmaniasis: Clinical and epidemiological features of children in an endemic area. J Paediatrics. (Brazil) 2004;80(2):141-146.
21. Schaefer KU, Kurtzhals JA, Sherwood JA, Githure JI, Kager PA, Muller AS. Clinical features and epidemiology of visceral leishmaniasis in Baringo, Kenya: A literature review. Trop Geogr Med. 1994;46(3):129-133.
22. Raina S, Mahesh DM, Kaul R, Satinder KS, Gupta D, Sharma A, et al. A new focus of visceral leishmaniasis in the Himalayas, India. J Vector Borne Dis. 2009;46:303-306.
23. Mehrrota S, Fakiola M, Mishra A, Sudarshan M, Tiwary P, Rani DS, et al. Genetic and functional evaluation of the role of DLD1 in susceptibility to visceral leishmaniasis in India. Infection, Genetics, and Evolution. 2012;12:1195-1201.
24. Zijlstra EE, Musa AM, Khalil EA, Elhassan IM, Elhassan AM. Post-kalaazar dermal leishmaniasis. Lancet Infect Dis. 2003;3(2):87-98.
25. Pastorino AC, Jacob CM, Oselka GW, Sampaio MM. Visceral leishmaniasis: Clinical and laboratory aspects. J Paediatrics. (Brazil) 2002;78:120-127.
26. Costa HN, Pereira HF, Araujo MV. Epidemiology of visceral leishmaniasis in Brazil 1980-1986. Rev Saude Publica. 1990;24(5):361-372.